All In MedTech

Device Trial Radar · NCT06966427

Prospective Evaluation of a Dose Guidance System for People With Diabetes Initiating Basal Insulin or Using Insulin Injections

Last checked: Nov 19, 2026Latest source record: May 11, 2025 (this record)Source: ClinicalTrials.govMethods & limitations

Recruiting

Status

Recruiting

Enrollment

45

Planned (sponsor's estimate)

Start

May 8, 2025

Primary completion

May 25, 2026

Study completion May 25, 2026

Sponsor

Lead sponsor
Rabin Medical CenterAcademic, hospital or other
Sponsor type
Academic, hospital or other
Collaborators
DreaMed Diabetes
First posted
May 11, 2025

More device trials from this sponsor

Design

Study type
Interventional
Phase
Not applicable (typical for device studies)
Allocation
Randomized
Model
Parallel
Masking
Single (participant)
Primary purpose
Treatment
FDA-regulated device
No
Who can join
All sexes, from 6 years, up to 75 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

A prospective, randomized, single blind, two-arms, multicenter study. The study aims to assess the safety of a dosing-guided system (DGS) that provides direct advice on insulin dosing recommendations and diabetes management to individuals with diabetes using insulin or starting basal insulin therapy, guided by their continuous glucose monitoring (CGM). The study population will include up to 45 individuals with diabetes, distributed as follows: 15 with Type 1 diabetes (T1D) and 15 with Type 2 diabetes (T2D), both on MDI therapy and 15 with T2D using or starting to use basal insulin. The study will include a 2- to 4-week run-in period followed by a 6-week intervention period.

Conditions

  • Type 1 Diabetes
  • Type 2 Diabetes

Interventions

  • Dosing Guidance System to be used with both time and amount of insulin as inputDevice

    Any insulin dosing event manually logged by the participant, the DGS will receive the time and amount of the dose as input

  • Dosing Guidance System to be used with only time of insulin as inputDevice

    any insulin dosing event manually logged by the participant, the DGS will receive only the time of the dose as input

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Sensor glucose percentage of time in hypoglycemia below 54 mg/dLTime frame: Aafter 6 weeks of intervention period

Locations

2 sites in 2 countries. Site status is shown where the registry gives one.

  • Schneider Children Medical Center of Israel

    Petah Tikva, Israel · Not yet recruiting

  • University Medical Center of Ljubljana

    Ljubljana, Slovenia · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.